Trial Profile

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque Psoriasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX-629 (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; Proof of concept
Sponsors Aldeyra Therapeutics

Most Recent Events

05 May 2022 Status changed from recruiting to completed.
29 Mar 2022 According to an Aldeyra Therapeutics media release, results from this trial were presented at 2022 Research & Development Day.
29 Mar 2022 Results published in an Aldeyra Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com